The thrombopoietin receptor agonist eltrombopag may accelerate platelet recovery in older patients being treated for AML.
The guidelines recommend treatment over supportive management as well as more intensive therapy when it can be tolerated.
A computer model developed by Cleveland Clinic Cancer Center researchers and their colleagues who applied machine learning to clinical and genomic datasets is able to predict the survival of individual acute myeloid leukemia patients more accurately than existing models.
Cleveland Clinic Cancer Center’s new CHIP Clinic will screen and monitor patients with potentially disease-causing somatic mutations called clonal hematopoiesis of indeterminate potential (CHIP) in blood or bone marrow cells.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Two related Cleveland Clinic studies examining acute myeloid leukemia outcomes in various patient populations bolster the case for easing some restrictions on clinical trial enrollment, which could increase access for patients who potentially could benefit and produc less racially biased, more generalizable results.
Treatment-related toxicities from conventional chemotherapy can cause suffering in many patients with childhood leukemia. The search continues for medications that are effective while producing fewer adverse effects. Pediatric hematologist/oncologist, Seth Corey, MD, MPH, explains his latest study repurposing the antimalarial drug, mefloquine.
Evidence regarding the genetic pathways involved in Scwachman-Diamond syndrome and severe congenital neutropenia is emerging. Clinician researcher Seth Corey, MD, MPH, explains his work to identify patients at highest risk and intervene before acute myeloid leukemia develops.
Azacitidine could help patients with acute myelogenous leukemia or myelodysplastic syndrome who relapse after transplant achieve remission.
Although studies have established the prognostic significance of specific genetic mutations in AML and MDS, the role of mutations as prognostic factors of outcomes after HCT is still unclear.
Abandoning apoptosis in favor of selective differentiation has proven a fruitful strategy in the search for AML treatments.